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Background: Mitochondrial diseases, a group of multi-systemic disorders often characterized by tissue-specific
phenotypes, are usually progressive and fatal disorders resulting from defects in oxidative phosphorylation.
MTO1 (Mitochondrial tRNA Translation Optimization 1), an evolutionarily conserved protein expressed in high-
https://doi.org/10.1016/j.ymgme.2017.11.003
Received 28 July 2017; Received in revised form 11 November 2017; Accepted 11 November 2017
⁎ Corresponding author at: Centre for Molecular Medicine and Therapeutics, University of British Columbia, 980 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada.
1 Authors contributed equally.
2 Current affiliation: Departments of Biochemistry, Molecular Biology and Medical Genetics, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of
Calgary, Calgary, AB, Canada.
E-mail address: cvankarnebeek@cw.bc.ca (C.D.M. van Karnebeek).
Abbreviations: GDD, global developmental delay; HCM, hypertrophic cardiomyopathy; ID, intellectual disability; MRI, magnetic resonance imaging; MTO1, Mitochondrial tRNA
Translation Optimization 1; OXPHOS, oxidative phosphorylation; Q-TOF, quadrupole time-of-flight; WES, whole exome sequencing
Molecular Genetics and Metabolism 123 (2018) 28–42
Available online 15 November 2017
1096-7192/ © 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/).
T
Ketogenic diet
Mitochondrial translation optimization 1
Oxidative Phosphorylation Defect
energy demand tissues has been linked to human early-onset combined oxidative phosphorylation deficiency
associated with hypertrophic cardiomyopathy, often referred to as combined oxidative phosphorylation defi-
ciency-10 (COXPD10).
Material and methods: Thirty five cases of MTO1 deficiency were identified and reviewed through international
collaboration. The cases of two female siblings, who presented at 1 and 2 years of life with seizures, global
developmental delay, hypotonia, elevated lactate and complex I and IV deficiency on muscle biopsy but without
cardiomyopathy, are presented in detail.
Results: For the description of phenotypic features, the denominator varies as the literature was insufficient to
allow for complete ascertainment of all data for the 35 cases. An extensive review of all known MTO1 deficiency
cases revealed the most common features at presentation to be lactic acidosis (LA) (21/34; 62% cases) and
hypertrophic cardiomyopathy (15/34; 44% cases). Eventually lactic acidosis and hypertrophic cardiomyopathy
are described in 35/35 (100%) and 27/34 (79%) of patients with MTO1 deficiency, respectively; with global
developmental delay/intellectual disability present in 28/29 (97%), feeding difficulties in 17/35 (49%), failure
to thrive in 12/35 (34%), seizures in 12/35 (34%), optic atrophy in 11/21 (52%) and ataxia in 7/34 (21%).
There are 19 different pathogenic MTO1 variants identified in these 35 cases: one splice-site, 3 frameshift and 15
missense variants. None have bi-allelic variants that completely inactivate MTO1; however, patients where one
variant is truncating (i.e. frameshift) while the second one is a missense appear to have a more severe, even fatal,
phenotype. These data suggest that complete loss of MTO1 is not viable. A ketogenic diet may have exerted a
favourable effect on seizures in 2/5 patients.
Conclusion: MTO1 deficiency is lethal in some but not all cases, and a genotype-phenotype relation is suggested.
Aside from lactic acidosis and cardiomyopathy, developmental delay and other phenotypic features affecting
multiple organ systems are often present in these patients, suggesting a broader spectrum than hitherto reported.
The diagnosis should be suspected on clinical features and the presence of markers of mitochondrial dysfunction
in body fluids, especially low residual complex I, III and IV activity in muscle. Molecular confirmation is required
and targeted genomic testing may be the most efficient approach. Although subjective clinical improvement was
observed in a small number of patients on therapies such as ketogenic diet and dichloroacetate, no evidence-
based effective therapy exists.
1. Introduction
Mitochondrial diseases encompass a broad range of disorders that
may result from pathogenic mutations of mitochondrial DNA or the
nuclear genome and affect all ages in a mono- or multisystemic
manner with an estimated prevalence of ~1:5,000 [1,2]. Approxi-
mately 1200 different nuclear genes encode mitochondrial proteins
and causal defects have been identified in ~300 genes, many
through genome wide sequencing approaches [3,4]. Continued
identification of nuclear genes associated with mitochondrial disease
will result in a greater understanding of mitochondrial homeostasis
and function [5].
A novel form of mitochondrial disease caused by mutations in
MTO1, encoding the mitochondrial tRNA translation optimization 1
(MTO1) protein (OMIM#614667) was first described in 2012 in 2
Italian siblings, born of unrelated parents, presenting soon after birth
with lactic acidosis, severe hypoglycaemia and fatal infantile hy-
pertrophic cardiomyopathy [6,7]. MTO1 is one of two subunits of an
enzyme that catalyzes the 5-carboxymethylaminomethylation of the
wobble uridine base in the mitochondrial tRNAs specific to leucine,
tryptophan, glutamine, glutamic acid and lysine [8–10]. This post-
transcriptional modification is critical to the accuracy and efficiency
of mtDNA translation. As is observed with other nuclear-mitochon-
drial diseases of mt-tRNA modification such as TRIT1, TRMT5,
GTPBP3 and PUS1, MTO1 deficiency usually results in a combined
reduction of mtDNA-dependent respiratory chain activities
[6,11–14].
Hallmark features of MTO1 deficiency include hypertrophic cardi-
omyopathy (HCM), lactic acidosis (LA) and mild to severe global de-
velopmental delay (GDD)/intellectual disability (ID) [6,15] but sig-
nificant phenotypic heterogeneity exists. Two female siblings with
MTO1 mitochondriopathy who remain without CM at the adolescent
age are presented in detail in this paper. A mouse model of the MTO1
deficiency was recently generated, and shown to have similar to human
phenotype [16]. Using the mouse embryonic fibroblasts from the
MTO1-deficient mice, it was recently demonstrated that MTO1 controls
mitochondrial translation rate via mt-tRNA modification in a tissue-
specific manner [11]. This explains the organ specific pathologies and
the reported phenotypic heterogeneity. The aim of this study was to
review and report on 35 cases of MTO1-deficient mitochondrial disease,
outlining their clinical and molecular features, response to treatment
and genotype-phenotype evaluation.
2. Cases and methods
2.1. Clinical descriptions
Two female siblings and their parents were enrolled into the
Treatable Intellectual Disability Endeavour eXome (TIDEX) neuro-
metabolic discovery study (UBC IRB approval H12-00067) [17].
Written consent for data and sample collection, whole exome se-
quencing (WES), as well as publication of the current case reports
was provided by the parents. Consent for publication of the other
cases mentioned in the tables was provided to the clinician or la-
boratory scientist at the respective institutions. These naturally
conceived children were born to non-consanguineous parents of
Caucasian (paternal) and Malayo-Polynesian ethnicity (maternal).
Family history was significant for a maternal uncle with ID, a ma-
ternal aunt and first cousin with a history of febrile seizures, and a
maternal first cousin with speech delay and hyperactivity.
Case 1: this 16-year-old female presented with early onset mild
developmental delay and atypical febrile seizure at 2.5 years with
subsequent absence seizures at 3.5 years. She was born at 38 weeks
gestation, by spontaneous vaginal delivery, weighing 3.34 kg. She sat
unsupported at 8 months of age and started to cruise at 12 months.
First concerns were raised with speech delay (first words were at
2 years). Physical exam at age 4 years showed hypotonia with mod-
erate delay in gross motor, fine motor, expressive language
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(approximately 100 words) and social skills. Plasma and CSF lactate
levels were elevated at 4.4 mmol/L (ref range: 0.5–2.2 mmol/L) and
3.3 mmol/L respectively. Plasma amino acids demonstrated in-
creased alanine of 657 μmol/L (reference range 148–475 μmol/L).
Respiratory chain analysis on muscle biopsy showed complex I and
IV deficiency (complex I activity: 4.1 nmol/min/mg (ref range
17.9–56.7); complex IV activity: 0.76 nmol/min/mg (ref range
2.3–5.03)). Pathological analysis of the muscle demonstrated a
greater number of type 1 than type 2 fibres with variation in fibre
size diameter but no histological, histochemical or ultrastructural
features to suggest a mitochondrial myopathy. She was commenced
on oral L-carnitine, thiamine and riboflavin, with coenzyme q10,
vitamin E, and vitamin D added later.
At age 6 years, the patient was ataxic with generalized muscle
weakness, was unable to ride a tricycle, and could only make 2–3
word sentences. She experienced behavioural change with the onset
of aggressiveness and pica. At 7 years a ketogenic diet was started
(highest ratio 4.75:1) which initially reduced her seizure activity, but
six months after commencement, in the context of a severe flu-like
illness, she developed a sudden reduction in bilateral visual acuity
(10/400), ptosis and generalised weakness. Fundoscopy demon-
strated bilateral optic disk pallor, localized to the papillomacular
bundle. MRI brain was normal at 3 and 8 years, but at age 9 years a
signal abnormality in the midline of the brain and in the optic chiasm
was detected on T2 imaging. At 11 years she presented in status
epilepticus and CT/MRI brain imaging demonstrated multiple areas
of hyperintense T2/FLAIR signal within the cerebral peduncles, basal
ganglia and cortex most likely due to a metabolic crisis which had
largely resolved one week later. Seizures proved refractory to treat-
ment and the ketogenic diet was reduced to a 2:1 ratio at age
12 years. This was followed by an improvement of her visual acuity
and subjective energy levels.
The phenotype evolved and assessment at 16 years of age showed
moderate ID requiring a special life skills program in school, optic
neuropathy with good visual acuity in both eyes, bilateral ptosis,
mild facial weakness, myopathic ataxia with mild dysmetria with
intention tremor and dysarthria with decreased muscle mass and
proximal muscle strength but without bulbar symptoms and con-
stipation. Echocardiography (ECHO) was unremarkable at age
15 years. Short stature between ages 8 to 15 years (height less than
3rd centile and weight on the 3rd centile), prompted an en-
docrinology work-up which showed no evidence of hormonal ab-
normalities and at 16 years her height and weight were normal
(3rd–10th centile). Head circumference remained normal (between
mean and +1 SD). The patient’s seizures were poorly controlled and
she continued to have up to 40 seizures per week on a ketogenic diet
(2:1), levetiracetam, piracetam, clonazepam and rufinamide which
varied from generalized, absence, to drop seizures. Hearing assess-
ment was normal.
Case 2 is a 12-year-old full female sibling who presented with a
similar albeit milder phenotype, with febrile seizures at 19 and
26 months and subsequently developed afebrile seizures. She was
born at 40 weeks gestation, by spontaneous vaginal delivery,
weighing 3.85 kg. During the pregnancy, maternal gestational dia-
betes was present which required insulin from 7 months gestation. At
3.5 years elevated plasma lactate (3.2–4.2 mmol/L; ref range
0.5–2.2 mmol/L) and alanine (711 μmol/L; ref range 148–475 μmol/
L) were noted. At 3 years the patient was considered devel-
opmentally appropriate but at 4.5 years she required aid in pre-
school. She was dysarthric with generalized weakness, and tended to
trip when walking. At 4 years she started on oral riboflavin,
coenzyme Q10, L-carnitine. Cranial MRI/spectroscopy and electro-
myography/nerve conduction studies were normal. Respiratory
chain analysis on muscle biopsy showed complex I and IV defi-
ciencies (complex I activity – 11.3 nmol/min/mg (ref range
17.9–56.7) and complex IV- 02.16 nmol/min/mg (ref range
2.3–5.03)). Pathology, including histochemistry and electron mi-
croscopy was normal.
Ophthalmological and audiological exams as well as ECHO were
normal at 5 and 12 years respectively. At 12 years, she showed mod-
erate ID and attended mainstream school with an adapted program. She
had normal muscle strength in her face and limbs with mild hypotonia
and no bulbar symptoms. Her deep tendon reflexes were normal. Her
seizures varied and were well controlled with clobazam, levetiracetam,
lamotrigine and ethosuximide. Hence the modified Atkins diet was not
attempted. Growth parameters were consistently normal with height
and weight between the 90th–95th centile and her head circumference
between 25th–50th centile. For a clinical summary of these two cases
see patient numbers 4 and 5 of Table 1.
2.2. Whole exome sequencing for the two presented siblings
Quad-WES analysis (index-affected sibling-unaffected mother-un-
affected father) using the Agilent SureSelect kit and Illumina HiSeq
2000 (Perkin-Elmer, USA) was performed. The data was analysed using
our semi-automated bioinformatics pipeline [17]: (1) the sequencing
reads were aligned to the human reference genome version hg19 using
Bowtie 2 [18], (2) the duplicates were marked and sorted using Picard,
(3) variants were called using SAMtools and BCFtools after indel rea-
lignment using GATK, (4) transcripts were annotated using snpEff [19],
(5) functional variants were prioritized for rare variants by comparison
against the public databases [dbSNP, NHLBI Exome Sequencing Project
Exome Variant Server, and Exome Aggregation Consortium (ExAC)]
and (6) subsequently screened under a series of Mendelian inheritance
models: homozygous, hemizygous, compound heterozygous and de
novo as described previously [20].
2.3. Identification and review of 35 cases of MTO1 deficiency
Through a PubMed literature search (2012–2017) and direct contact
with clinical colleagues caring for mitochondrial diseases patients, we
identified and collected clinical and genotypic information on a further
33 patients (18 published and 15 unpublished) with pathogenic muta-
tions in MTO1. The data on the total of 35 patients were collated in
Excel. Statistical analysis was limited to descriptive and confidence
interval calculations (https://www.pedro.org.au/english/downloads/
confidence-interval-calculator/).
3. Results
3.1. WES analysis for the two female siblings and parents
Whole exome sequencing (WES) identified three candidate genes
(CDH23, C5orf42 and MTO1), all three with compound heterozygous
variants. Of these three candidate genes, the variants on chromosome
6 affecting the MTO1 protein were deemed to be the best explanation
for the observed phenotype in the siblings. Both affected siblings are
compound heterozygous (Supplementary Fig. 1) for two variants
(c.1451G > A; p.Arg484Gln) and (c.1273G > A; p.Gly425Arg) in
MTO1 (NM 012123.3; NP 036255) on chromosome 6 which are
predicted in silico to be damaging by all tested tools. One of the
variants, p.Arg484Gln, is novel and had not been observed in
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analysed databases, including dbSNP (v.142), NHLBI ESP, in – house
or ExAC while the second variant, p.Gly425Arg, had been reported
once in the ExAC database (Table 2). Sanger sequencing confirmed
segregation with disease according to the recessive inheritance
model, with carrier status in each parent.
3.2. Clinical phenotypic spectrum (Table 1 and Supplementary Table 1)
Despite best efforts complete data for all cases was not possible to
ascertain which has resulted in a variation of the denominator from 35.
An overview of clinical features of the 35 patients (17 males and 18
females) from 11 different countries (Austria, Canada, Croatia,
Germany, India, Italy, Pakistan, Turkey, Spain, Syria and the United
Kingdom) is presented in Table 1.
12/35 (34%) cases are offspring to consanguineous parents. 15/34
(44%) presented in the first 2 days of life. The average age of pre-
sentation was 10.2 months (range: day 1 to 8.0 years).
At the time of writing 12/35 (34%) patients were deceased with an
average age of death of 2.67 years (range: week 1 to 23 years). 8/17
(47%) of males passed away at an average age at death of 0.96 years
(week 1 to 3.25 years). 4/18 (22%) of females were deceased with an
average age at death of 6.1 years (7 months to 23 years). Of those
presenting clinically in the first 2 days of life, 7 patients (47%) passed
away before the age of 2 years, suggesting a relationship between
earlier presentation and a poorer prognosis.
The most common clinical feature at initial presentation was
hypertrophic cardiomyopathy (HCM), present in 15/34 [44%; 95%
CI, 29–60%] cases which over time developed in 27/34 [79%; 95%
CI, 63–90%] cases. Of note one patient (patient no.12) developed
dilated CM which may have been HCM at an earlier stage. Hypotonia
was identified in 10/35 [29%; 95% CI, 16–45%] cases at presenta-
tion but it eventually occurred in 22/35 [63%; 95% CI, 46–77%]
cases. GDD/ID affected 28/29 [97%; 95% CI, 83–99%] cases for
whom this information was available; one patient was described to
have normal scholastic performance at age 19 years. Failure to thrive
(FTT) was reported in 12/35 [34%; 95% CI, 21–51%] cases, and
feeding difficulties in 17/35 [49%; 95% CI, 33–64%] cases. Optic
atrophy occurred in 11/21 [52%; 95% CI, 32–72%] cases with
thinning of the retinal nerve fibre layer documented in three of these
cases. Other ocular pathology noted in this case series included ex-
ternal ophthalmoplegia (1/20 cases), unilateral ptosis (1/20 cases)
and mild bilateral cataracts (1/20 cases). Seizures were not a fre-
quent initial symptom (only present in 5/35 [14%; 95% CI, 6–29%]
but developed over time in 12/35 [34%; 95% CI, 21–51%] cases.
Ataxia was diagnosed in 3/34 [9%; 95% CI 3–23%] cases at initial
presentation and during follow-up in 7/34 [21%; 95% CI, 10–37%].
Hepatic dysfunction was infrequent, present in 3/35 [9%; 95% CI,
3–22%]. Renal involvement was also infrequent (1/35 [3%; 95% CI
0.5–14%]). Renal dysfunction, present in patient 12 is thought to be
secondary to CM and poor perfusion.
All cases of MTO1 deficiency presented with a combination of the
above described clinical features. There was no documented history of
diabetes or ptosis and only one documented case of hypoglycaemia.
Cranial MRIs were reported normal in 6/20 patients in whom it was
performed [30%; 95% CI, 15–52%]. Documented abnormalities in the
14/20 [70%; 95% CI, 48–85%] cases included lesions of the basal
ganglia and cerebellar peduncles and hypoplasia of the corpus cal-
losum. An elevated lactate peak on brain scan was identified in 2/5
cases in whom spectroscopy was performed. (Table 1 and Supplemen-
tary Table 1)
3.3. Genotypic spectrum (Table 2)
In the 35 patients from 26 unrelated families, we identified 19
different MTO1 (NM 012123.3; NP 036255) variants (7 published
and 12 unpublished): 15 missense, 3 frameshifts and one splice-siteTa
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Table 2
Overview of the genotypic data of patients with confirmed MTO1 deficiency.
Patient no Nucleotide change Protein change Inheritance In silico prediction scores ExAC frequency
1 c.1451G > A
c.1273G > A
p.Arg484Gln
p.Gly425Arg
Compound heterozygous CADD (33)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (34)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.000008237
2 c.1451G > A
c.1273G > A
p.Arg484Gln
p.Gly425Arg
Compound heterozygous CADD (33)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (34)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.000008237
3 c.1222 A > T p.Ile408Phe Homozygous CADD (29.1)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
4 c.963 A > C
c.1429 C > T
p.Lys321Asn
p.Arg477Cys
Compound heterozygous CADD (24.4)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0
5 c.1261-5T > G
c.1430G > A
p.Val422Ilefs*18
p.Arg477His
Compound heterozygous CADD (10.5)
SIFT (NA; splice-site)
PolyPhen2(NA; splice-site)
CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.0002307
6 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
7 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
8 c.122T > G
c.1282G > A
p.Val41Gly
p.Ala428Thr
Compound heterozygous CADD (26.1)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 0.998)
CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.00005766
9 c.1282G > A
c.402_403delTA
p.Ala428Thr
p.Tyr134Terfs
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
Frameshift
0.00005766
0.000008241
10 c.631-631delG
c.I282G > A
p.Gly211Aspfs*3
p.Ala428Thr
Compound heterozygous Frameshift
CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.00005766
11 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
12 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
13 c.122T > G
c.767A > G
c.1282G > A
p.Val41Gly
p.His256Arg
p.Ala428Thr
Compound heterozygous CADD (26.1)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 0.998)
CADD (10.27)
SIFT (TOLERATED; 0.097)
PolyPhen2(BENIGN; 0.000)
CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0
0.00005766
14 c.1282G > A
c.1858dup
p.Ala428Thr
p.Arg620Lysfs*8
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
Frameshift
0.00005766
0
15 c.1282G > A
c.1858dup
p.Ala428Thr
p.Arg620Lysfs*8
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
Frameshift
0.00005766
0
16 c.1282G > A p.Ala428Thr Homozygous CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00005766
17 Compound heterozygous
(continued on next page)
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Table 2 (continued)
Patient no Nucleotide change Protein change Inheritance In silico prediction scores ExAC frequency
c.1282G > A
c.1430G > A
p.Ala428Thr
p.Arg477His
CADD (34)
SIFT (DAMAGING; 0.002)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00005766
0.0002307
18 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
19 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
20 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
21 c.1232C > T p.Thr411IIe Homozygous CADD (33)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.00002472
22 c.1222A > T p.IIe408Phe Homozygous CADD (29.1)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
23 c.1273G > A
c.1417C > T
p.Gly425Arg
p.Arg473Cys
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.000008237
0
24 c.1273G > A
c.1417C > T
p.Gly425Arg
p.Arg473Cys
Compound heterozygous CADD (34)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.000008237
0
25 c.1390C > T
c.1430G > A
p.Arg464Cys
p.Arg477His
Compound heterozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.0002307
26 c.1390C > T
c.1430G > A
p.Arg464Cys
p.Arg477His
Compound heterozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.0002307
27 c.1430G > A
c.1450C > T
p.Arg477His
p.Arg484Trp
Compound heterozygous CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (34)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.0002307
0.0000165
28 c.1430G > A
c.1450C > T
p.Arg477His
p.Arg484Trp
Compound heterozygous CADD (35)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (34)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0.0002307
0.0000165
29 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
30 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
31 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
32 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
33 c.1390C > T p.Arg464Cys Homozygous CADD (35)
SIFT (DAMAGING; 0.000)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
34 c.1436A > T p. Asp479Gly Homozygous CADD (31)
SIFT (DAMAGING;0.002)
PolyPhen2(PROBABLY DAMAGING; 0.998)
0.000008241
(continued on next page)
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(Table 2 and Fig. 1). Please note that for consistency and proper
genotype-phenotype comparisons, we re-annotated all variants, in-
cluding those previously published, according to the NM 012123.3
transcript. The missense variants affect the conserved amino acids
located in the: FAD-binding domain (n = 1), insertion domain 2
(n = 1), GidA specific sequence motif (n = 5) and central helical
domain (n = 8) of the MTO1 [21]. All of the variants are extremely
rare and either not observed in the population databases or observed
at very low frequencies. All but two variants are predicted to be
damaging by in silico prediction tools (Table 2). Patient 13 was found
to have three rare variants in MTO1: p.(Ala428Thr) inherited from
father and p.(Val41Gly) and p.(His256Arg) both inherited from
mother. While the p.(Ala428Thr) and p.(Val41Gly) are predicted
damaging and have been described in other patients with MTO1
deficiency, the p.(His256Arg) variant inherited in cis with the p.
(Val41Gly) is predicted benign by tested tools and may not con-
tribute to the phenotype. In addition to p.(His256Arg), the splice-site
variant in patient 3 has lower than expected pathogenicity score and
the predicted effect on splicing is currently being tested experimen-
tally.
Of the 35 patients, 17 are homozygous and 13 compound het-
erozygous for missense variants, four are compound heterozygous for
a missense and a frameshift variant and one is compound hetero-
zygous for a missense and a predicted splice-site variant (Fig. 1 and
Table 2). None of the patients have bi-allelic truncating variants (i.e.
frameshift) suggesting that complete loss of MTO1 is unlikely to be
viable in humans. To determine to what extent the MTO1 genotype
may correlate with the clinical presentation, we first grouped the
patients according to the shared genotype. We observed that the four
patients from three unrelated families who are compound hetero-
zygous for the p.(Ala428Thr) variant and a frameshift variant appear
to have more severe presentation: earlier than average age of pre-
sentation of clinical features at 0.04 years and shorter than average
survival time at 0.24 years, further supporting the hypothesis that
residual MTO1 protein function is needed for survival. Beyond the
probands who are compound heterozygous for one truncating var-
iant, we also observed that probands homozygous for the p.
(Thr411Ile) variant tend to have more severe phenotype, while the
probands homozygous for the p.(Arg464Cys) variant tend to have
longer than average survival time.
3.4. Biochemical phenotypic spectrum (Table 3)
3.4.1. Clinical chemistry
The most frequent biochemical feature at initial presentation was
lactic acidosis, identified in 21/34 [62%; 95% CI, 45–76%] cases in
whom it was measured. Eventually, once tested it was present in all
patients, 35/35 (100%). The average recorded peak level of plasma
lactate of 13.6 mmol/L (range 3.4 to 57.8 mmol/L). An elevated plasma
alanine was documented in 21/24 [88%; 95% CI, 69–96%] cases with
the average recorded level of 1346 μmol/L (range 630–6560 μmol/L).
Markers of mitochondrial dysfunction, including lactate, ketones, TCA
(Krebs cycle) metabolites, tyrosine metabolites, dicarboxylic acids and
3-methylglutaconate, were eventually present in the urinary organic
acid profile in various patterns in every patient analyzed (14/14 [100%;
95% CI, 78–100%]) and CSF lactate was elevated in 5/6 cases [83%;
95% CI, 43–97%].
3.4.2. Respiratory chain analysis
Respiratory chain enzyme (RCE) analysis in muscle was performed
in 30 patients. Complex IV was deficient in 28/30 cases and 27/30
cases showed evidence of combined deficiency. Of the combined defi-
ciencies, complex I and IV deficiency were most commonly seen (20/30
cases) while combined complex I, III and IV deficiency, was present in
6/30 cases. In fibroblasts, RCE analyses varied from normal in 4/10
[33%] to a single complex deficiency in 2/10 [20%], while a combined
complex deficiency was present in 4/10 [40%]. Also in this tissue, the
most commonly observed biochemical defect was a combined complex I
and IV deficiency.
3.5. Treatments
Various combinations of vitamin/anti-oxidant supplements (the
‘mitochondrial cocktail’) according to each institution clinical prac-
tice were administered. Of the 35 patients, 8 did not have any
treatment directed towards primary mitochondrial dysfunction and
for 2 information is unavailable. Supportive treatments, not directed
at primary mitochondrial dysfunction such as inotropes and tube
feeding, were not recorded. For the remaining patients, 14/25 [56%]
cases were commenced on L-carnitine, 17/25 [68%] on co-enzyme
Q10, 6/25 [24%] on vitamin C, 4/25 [16%] on vitamin E, 11/25
[44%] on riboflavin and 5/25 [20%] on thiamine which had no ap-
preciable effect. Also, dichloroacetate was administered to 8/25
[32%] patients with the intent of lowering lactate levels. The keto-
genic diet was trialled in 5/22 [23%] patients, 3 of whom were
deemed unresponsive. Only one patient (patient 1) showed a clear
clinical improvement while in one other patient (patient 4) seizures
were initially better controlled after the start of the diet, but at
8 years, different seizures types developed (drop attacks) and the diet
fat ratio was reduced. Visual deterioration occurred soon after onset
of ketogenic diet in patient no. 4 and in retrospect, this symptom was
unlikely related to the diet, but rather the result of a secondary
complication of MTO1 deficiency.
Table 2 (continued)
Patient no Nucleotide change Protein change Inheritance In silico prediction scores ExAC frequency
35 c.1949C > T
c.722C > T
p.Thr650Ile
p.Pro241Leu
Compound heterozygous CADD (33)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
CADD (33)
SIFT (DAMAGING; 0.001)
PolyPhen2(PROBABLY DAMAGING; 1.000)
0
0.000008241
Genotypes of 35 patients with MTO1 deficiency including inheritance pattern (homozygous versus compound heterozygotes), in silico prediction scores (CADD, SIFT and Polyphen) and
frequency observed in the ExAC database (http://exac.broadinstitute.org/).
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4. Discussion
The current series of 35 cases with bi-allelic mutations in MTO1,
which encodes a ubiquitously expressed enzyme necessary for opti-
mization of mtDNA-dependent protein synthesis, is to our knowledge
the largest to date. Review of their clinical features confirmed as
hallmarks of this primary mitochondrial disease developmental/
cognitive impairment, lactic acidosis and complex IV deficiency
( ± other deficiencies) in muscle (http://www.proteinatlas.org/
ENSG00000135297-MTO1/tissue). Two patients are presented in
detail to illustrate the wide phenotypic spectrum of MTO1 defi-
ciency, i.e. that a typical clinical presentation for this condition does
not exist and thus must be considered in patients with a variety of
features. Although early reports suggested that HCM at a young age
to be pathognomonic for MTO1 deficiency, HCM was absent in both
presented adolescent siblings. A further four cases of MTO1 defi-
ciency without cardiomyopathy at ages 0.66 to 22 years, one pub-
lished and three unpublished, were identified in our review.
Together, these six cases prove that HCM is not a hallmark clinical
feature of this condition; in fact it was only reported as a presenting
feature in approximately half of cases (see Table 1). Although in
MTO1 deficiency the cardiomyopathy is usually hypertrophic, one
patient developed a dilated form (patient 12) which we recognize
may be a progression from HCM. As is common in rare diseases, the
phenotype of MTO1 deficiency appears more variable than initially
thought.
Other commonly occurring clinical features identified were
feeding difficulties, FTT, hypotonia and ocular pathology. Frequently
occurring biochemical characteristics include elevated plasma ala-
nine and mitochondrial markers in urine. This review also identified
a broad phenotypic spectrum for MTO1 deficiency from a severe,
rapidly progressive, ultimately fatal presentation in the neonatal
period to that of an 8-year-old presenting with ID, fatigability and
clumsiness and surviving to adulthood to that of a 19-year-old male
who presented at age 1 month with feeding difficulties, poor ocular
fixation and HCM with reversal of many of his symptoms with by
Fig. 1. Protein sequence alignments of human MTO1 protein with orthologs. Sequence alignment of the human MTO1 protein with orthologs from Chlorobium tepidum, Escherichia coli,
Thermotoga maritima and Saccharomyces cerevisiae. The conserved amino acids are shaded and identified mutations in the cohort of 35 patients are denoted. The domain and motif
locations are depicted by coloured lines according to previously published work by Meyer et al. [21].
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1 year. At 19 years this patient has a recurrence of HCM but has
normal scholastic performance (Table 1).
The cohort of patients reviewed here further delineates the gen-
otype-phenotype relationship in MTO1 deficiency [7]. Consistent
with previous reports of an early-onset for the majority of mi-
tochondrial diseases involving the respiratory chain [22], almost
50% of our cohort presented in the first two days of life and the re-
mainder presented by end of childhood, which is unsurprising for a
deficiency of an enzyme so ubiquitously expressed and involved in
such a fundamental process as posttranscriptional modification of
specific mt-tRNAs [4,5]. Of those who presented in the first two days
of life, 50% were deceased by two years suggesting a positive cor-
relation between early neonatal presentation and an unfavourable
prognosis, an observation supported by Martin et al. [23]. Im-
portantly, all of the patients who are compound heterozygous for a
missense variant and a frameshift variant had early presentation and
shorter than average survival time; none of the 35 cases had bi-allelic
truncating MTO1 alleles, suggesting that residual MTO1 protein
function is needed for survival in humans. An unexpected observa-
tion was that the sex ratio of those who are deceased is skewed to-
ward males, the cause of which is unexplained. To date cases have
been reported in 11 different countries suggesting that MTO1 defi-
ciency is probably a pan-ethnic condition (see Table 1).
The most frequent neurologic features of primary mitochondrial
disease are muscle weakness with hypotonia, followed by clinical or
imaging features of central neurological disease and cognitive im-
pairment/decline [22,24–26]. In the presented cohort, clinical pre-
sentation for the majority was during the neonatal period when
global developmental delay is difficult to assess. Virtually all of the
patients for whom clinical information was available at a later age
did show an intellectual developmental disorder and/or other neu-
rologic impairment. Seizures were documented in approximately
one-third of cases while abnormalities of brain structure (including
anomalies of the claustrum and surrounding capsule, thalami, sub-
cortical white matter, cerebellar peduncles and the corpus callosum)
and an elevated lactate peak on spectroscopy were reported in more
than three-quarters of cases who underwent brain imaging. (Table 1
and Supplementary Table 1).
Interestingly, the phenotype differs between MTO1 and other pro-
teins involved in post transcriptional modification of specific mt-tRNAs,
such for example tRNA 5-methylaminomethyl-2-thiouridylate methyl-
transferase deficiency (TRMU) [27,28]. While TRMU mutations may
result in severe infantile hepatopathy or renal failure neither hepato-
pathy nor renal pathology are common features in MTO1 deficiency
with each observed in fewer than 10% of cases [29–31]. These may
however be features that will develop later in life.
Although the diagnosis of MTO1 deficiency may be suggested by the
presence of mitochondrial markers, such as plasma lactate, amino acids,
urinary mitochondrial markers and CSF lactate; these are not specific
(Table 3). Accordingly, the majority of cases were diagnosed by whole
or targeted exome sequencing rather than single gene tests. Respiratory
Chain Enzyme (RCE) analysis of muscle is a sensitive (though not
specific) test for MTO1 deficiency with enzyme deficiencies in all cases
known to date.
Given the role of MTO1 as an optimizer of mtDNA translation it is
not surprising that MTO1 mutations can be associated with impaired
mitochondrial protein synthesis and result in any combination of RC
deficiencies, from isolated complex IV deficiency to a combined
complex I and complex IV deficiency, the most commonly observed
biochemical signature. Complex I, III and IV deficiency, or isolated
deficiencies of complex I or complex IV were seen in a few patients.
This may be explained by the destination of the 13 mtDNA encoded
proteins; seven are core subunits of complex I, three of complex IV, two
of complex V (although this OXPHOS component cannot be easily
measured in frozen diagnostic muscle samples) and one of complex III;
complex II is entirely nuclear-encoded. Importantly the high number of
normal results in fibroblasts indicates that normal RCE analysis in this
cell type do not exclude the possibility of a MTO1 defect. Given the lack
of specificity and invasiveness of some of these tests (muscle biopsy)
targeted WES approach may be the single most effective diagnostic
approach to MTO1 deficiency which is illustrated by the two presented
cases.
Since the first diagnosed case of MTO1 deficiency in 2012, many
cases have been trialled on several therapies such as L-carnitine,
coenzyme Q10, vitamin C, riboflavin, thiamine, dichloroacetate
(DCA) and/or vitamin E. Despite the use of multiple variations of this
“mitochondrial cocktail”, documented objective improvement was
rare. As MTO1 is a FAD moiety-containing enzyme, riboflavin sup-
plementation was investigated as a possible treatment without ob-
served success in either respiratory chain or fibroblast oxygen con-
sumption analyses [6]. One such case where clinical and biochemical
improvement was noted was in patient no. 16 (Table 1). In this case
DCA is thought to have resulted in a marked improvement in LA
without side effects reported. HCM also improved resulting in a
normal ECHO at 9 months and a normal scholastic performance at
19 years [6]. The authors recognise that DCA is expected to improve
LA without a clear effect on seizures or neurological outcome [32].
Whether or not DCA had a direct positive effect on HCM in patient
no. 16 is uncertain and the improvement may have been part of the
natural disease course in this case. One of the three patients with
MTO1 deficiency described by Martin et al. is also reported to have
improved on therapy. This report however should be viewed cau-
tiously as this patient also had vitamin B12 deficiency and secondary
hyperhomocystinemia; the improvement might have been due to
treatment of this deficiency rather than the MTO1 mitochondrio-
pathy as the lactic acidemia persisted [33]. Clinical improvement
was recorded in one of five patients trialled on ketogenic diets. At
age 19 months persistently high lactate levels (between 3 and
7 mmol/l) were present. After several months on a moderate keto-
genic diet the lactate levels normalized and they remain normal at
the time of publication. Improvement in motor development was
observed, as the patient learned to walk soon after starting the diet
and at 4 years of age he was able to walk several hundred meters
despite remaining ataxic. Speech development remained poor with
the expressive domain more severely affected than receptive. His
initial mild cardiomyopathy resolved completely which the authors
recognize may have been the cause of his lactic acidemia and he
never developed seizures. Our female index initially also showed an
improvement on a ketogenic diet but subsequently her seizures
worsened. Thus the current data are insufficient to draw conclusions
about the effectiveness of the ketogenic diet; given the clinical im-
provement in the two patients described above, it may be worth
cautiously considering this treatment in MTO1 deficient patients
with seizures, especially in light of the report of amelioration of the
defects in oxidative phosphorylation observed in MTO1 KO mice on a
ketogenic diet [11]. Of note Bartsakoulia et al suggests that N-acetyl-
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cysteine supplementation may have a beneficial effect on mi-
tochondrial translation in MTO1 deficient fibroblasts and this is a
future potential treatment [34].
The authors acknowledge several limitations in the study.
Although features such as LA and HCM seem to be the clinical hall-
mark of MTO1 deficiency, caution must be observed given the pos-
sible ascertainment bias introduced by the preselection based on the
presence of these symptoms. Also, because the ages of the patients
differ with varied follow-up duration and quality, symptoms occur-
ring later in life may go unreported. An unexpected observation was
that the sex ratio of those who are deceased is skewed toward males.
This is unusual for a recessive condition and the authors recognize
that there is no obvious biological reason for this and it may be an
artefact of a small cohort. Although great care was used in compiling
the data kindly provided by clinicians and scientists in different parts
of the world, the authors recognize a potential limitation in the study
was the lack of usage of uniform terminology for clinical and bio-
chemical signs and symptoms. We strongly advocate for use of
Human Phenotype Ontology (HPO) (http://human-phenotype-
ontology.github.io/) terms to enhance standardization, which will
facilitate and improve such studies in the future. Furthermore, in the
literature and lab reports, multiple transcript variants encoding at
least 3 different MTO1 isoforms are used which has a potential for
confounding reporting and interpretation. Isoform a (NM_012123.3)
was chosen and in those papers where isoform b (NM_133645,
NP_598400) or c (NM_001123226, NP_001116698) was used, the
amino acid position was corrected according to isoform a, for con-
sistency in this study.
In summary, the mitochondrial disease knowledgebase is expanded
with this report on the largest cohort of MTO1 deficient patients to date
and discussion about the phenotype (clinical and biochemical), geno-
type, natural history, outcomes and treatments. The features of MTO1
deficiency are non-specific which can make accurate diagnosis difficult,
often requiring exome sequencing or gene panel analysis. We do re-
commend that physicians should consider this disease in patients with
LA, developmental/cognitive delay and other features of mitochondrial
disease. The report of three cases (the two presented siblings and case
no. 35) without cardiomyopathy at the adolescent age/early twenties
demonstrates that it is not an obligatory feature of the disease, which is
important for differential diagnostics. RCE analysis on muscle rather
than fibroblasts is recommended as the latter can yield false negative
results. Once further MTO1 deficiency patients are diagnosed/identi-
fied, development of phenotypic subgroups may become a possibility.
In general, early diagnosis is important for genetic counselling, prog-
nostication, screening for organ involvement, ending the diagnostic
odyssey and considering disease modifying interventions, such as the
ketogenic diet and, in the future, new therapies such as exosome-based
delivery [35].
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgme.2017.11.003.
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